A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Morsy, Mosaad INouman, Eman G
Abdallah, Youmna M
Zainelabdeen, Mourd A
Darwish, Mohamed M
Hassan, Ahmed Y
Gouda, Amira S
Rezk, Mamdouh R
Abdel-Megied, Ahmed M
Marzouk, Hoda M
Date
2021-04-01Journal
Journal of Pharmaceutical and Biomedical AnalysisPublisher
Elsevier B.V.Type
Article
Metadata
Show full item recordSee at
https://doi.org/10.1016/j.jpba.2021.114057https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015396/
Abstract
A novel, fast and sensitive LC-MS/MS method was developed and validated for the bioanalysis of the antiviral agent favipiravir (FAV); a promising candidate for treatment of SARS-CoV-2 (COVID-19) in human plasma using pyrazinamide as an internal standard (IS). Simple protein precipitation was adopted for plasma sample preparation using methanol. Chromatographic separation was accomplished on Eclipse plus C18 column (50 × 4.6 mm, 3.5 μm) using a mobile phase composed of methanol-0.2 % acetic acid (20:80, v/v) pumped at a flow rate 0.6 mL/min in an isocratic elution mode. The API4500 triple quadrupole tandem mass spectrometer was operated with multiple-reaction monitoring (MRM) in negative electrospray ionization interface for FAV and positive for IS. The MRM function was used for quantification, with the transitions set at m/z 156.00→ 113.00 and m/z 124.80→ 81.00 for FAV and IS. The method was optimized and fully validated in accordance to US-FDA guidelines. Linearity was acquired over a concentration range of 100.0-20000.0 ng/mL by computing using weighted linear regression strategy (1/x2). The proposed method was effectively applied for the pharmacokinetic evaluation of FAV and to demonstrate the bioequivalence of a new FAV formulation (test) and reference product in healthy Egyptian human volunteers.Rights/Terms
Copyright © 2021 Elsevier B.V. All rights reserved.Identifier to cite or link to this item
http://hdl.handle.net/10713/15396ae974a485f413a2113503eed53cd6c53
10.1016/j.jpba.2021.114057